BNP PARIBAS ARBITRAGE/PUT/MODERNA/110/0.01/20.12.24 Stock

Warrant

P216C3

NLBNPIT216C3

Market Closed - Borsa Italiana 04:04:59 2024-07-05 pm EDT
0.1195 EUR -1.65% Intraday chart for BNP PARIBAS ARBITRAGE/PUT/MODERNA/110/0.01/20.12.24
Current month+5.15%
1 month+114.91%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-05 0.1225 +0.82%
24-07-04 0.1215 -7.25%
24-07-03 0.131 +6.07%
24-07-02 0.1235 -3.52%
24-07-01 0.128 +9.87%

Real-time Borsa Italiana

Last update July 05, 2024 at 04:04 pm EDT

More quotes

Static data

Product typeWarrants
Buy / SellPUT
Underlying MODERNA, INC.
IssuerLogo Issuer BNP Paribas BNP Paribas
P216C3
ISINNLBNPIT216C3
Date issued 2024-03-26
Strike 110 $
Maturity 2024-12-20 (168 Days)
Parity 100 : 1
Emission price-
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.2135
Lowest since issue 0.0435
Delta-0.33x
Omega 2.987
Premium18.03x
Gearing9.1x
Moneyness 0.9297
Difference Strike -8.32 $
Difference Strike %-7.56%
Spread 0.003
Spread %2.47%
Theoretical value 0.1200
Implied Volatility 59.36 %
Total Loss Probability 51.66 %
Intrinsic value 0.000000
Present value 0.1200
Break even 96.99 €
Theta-0x
Vega0x
Rho-0x

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
More about the company

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Moderna, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.3 USD
Average target price
145.9 USD
Spread / Average Target
+23.27%
Consensus
  1. Stock Market
  2. Warrants
  3. P216C3 Warrant